Treatment Study for Radionecrosis after Radiosurgery for Brain Metastases
This randomized phase II study aims to investigate whether the addition of bevacizumab to standard corticosteroid therapy results in greater improvement in symptoms and less treatment-induced symptoms compared with standard corticosteroid therapy for patients with symptomatic brain radionecrosis following radiosurgery. It is hypothesized that the addition of bevacizumab to standard care corticosteroids will reduce treatment-induced toxicities and improve neurologic impairments in patients with brain radionecrosis following radiosurgery for brain metastases.
In order to participate you must meet the following criteria:
- Have a diagnosis of radionecrosis, which will be based on a clinical onset of symptoms and radiological findings of radionecrosis at 3-24 months following radiosurgery, with or without pathological confirmation.
- Are 18 years of age and older.
- Have no clinically significant cardiovascular disease.
This is a partial list of elgibility requirements.